UBS Group’s PaxMedica, Inc. Common Stock PXMD Stock Holding History

UBS Group’s Portfolio PXMD Stock Details PXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-491	Closed	-$372	–	10451
2023 Q4	$372	Buy	491 +426	+655%	+$987	﹤0.01%	8699
2023 Q3	$314	Buy	+65	New	+$629	﹤0.01%	8593
2023 Q2	–	Sell	-1,043	Closed	-$33.9K	–	10126
2023 Q1	$33.9K	Sell	1,043 -922	-47%	-$37K	﹤0.01%	6713
2022 Q4	$67.8K	Buy	1,965 +1,600	+438%	+$57.2K	﹤0.01%	6477
2022 Q3	$15K	Buy	+365	New	+$20.6K	﹤0.01%	7861

Other funds holding PXMD

SFA

Souders Financial Advisors Cincinnati, Ohio $876M AUM 14.39% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return

UBS Group's PXMD Position: Q1 2024 in Review

UBS Group sold out of PaxMedica, Inc. Common Stock (PXMD) in Q1 2024, closing a stake of 491 shares — an estimated $372 sold.

UBS Group first reported a position in PXMD in Q3 2022 and held it in 5 quarters. The position peaked at $67.8K in Q4 2022. 8 funds tracked by Wall St. Rank hold PXMD as of Q1 2024.

UBS Group reported no remaining PaxMedica, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
UBS Group sold 491 PaxMedica, Inc. Common Stock shares in Q1 2024, an estimated $372.
UBS Group first reported a position in PaxMedica, Inc. Common Stock in Q3 2022 and held it in 5 quarters.
UBS Group's PaxMedica, Inc. Common Stock position peaked at $67.8K in Q4 2022.
8 funds tracked by Wall St. Rank held PaxMedica, Inc. Common Stock as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.